Tricida CEO and leadership

Gerrit joined Relypsa in October 2007 after negotiating the Relypsa spin out transaction from Amgen as an advisor to the lead investor 5AM Ventures. He co-founded Ilypsa in 2003 while at Symyx Technologies. Between 2003 and 2007, Gerrit held varying positions at Ilypsa and was in charge of the series A and B financings on the company side and licensing deals with Astellas and Cubist. As Ilypsa’s Chief Business Officer, Gerrit co-led the M&A negotiations and diligence efforts. Prior to Ilypsa, he joined Symyx in 1998 as a Staff Scientist, and was later promoted to Director of Business Development. Gerrit received his Ph.D. in polymer chemistry from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He conducted postdoctoral research at Stanford University and the IBM Almaden Research Center.

Robert McKague joined Jazz Pharmaceuticals in October 2011. From 2010 to 2011, he served as Senior Counsel for Actelion Pharmaceuticals, Inc., where he provided compliance and legal guidance for all commercial departments. In 2009 and 2010, Mr. McKague served as Senior Corporate Counsel, Litigation for Oracle America. He was our Senior Corporate Counsel from 2006 to 2009, responsible for ensuring compliance with federal and state regulations for promotion and marketing. Prior to 2006, he held positions with Morrison & Foerster LLP and the Board of Governors of the Federal Reserve System. Mr. McKague received his J.D. from the University of California Hastings College of Law and his B.S. in International Relations and French from San Francisco State University.

Gerrit joined Relypsa in October 2007 after negotiating the Relypsa spin out transaction from Amgen as an advisor to the lead investor 5AM Ventures. He co-founded Ilypsa in 2003 while at Symyx Technologies. Between 2003 and 2007, Gerrit held varying positions at Ilypsa and was in charge of the series A and B financings on the company side and licensing deals with Astellas and Cubist. As Ilypsa’s Chief Business Officer, Gerrit co-led the M&A negotiations and diligence efforts. Prior to Ilypsa, he joined Symyx in 1998 as a Staff Scientist, and was later promoted to Director of Business Development. Gerrit received his Ph.D. in polymer chemistry from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He conducted postdoctoral research at Stanford University and the IBM Almaden Research Center.

Gerrit joined Relypsa in October 2007 after negotiating the Relypsa spin out transaction from Amgen as an advisor to the lead investor 5AM Ventures. He co-founded Ilypsa in 2003 while at Symyx Technologies. Between 2003 and 2007, Gerrit held varying positions at Ilypsa and was in charge of the series A and B financings on the company side and licensing deals with Astellas and Cubist. As Ilypsa’s Chief Business Officer, Gerrit co-led the M&A negotiations and diligence efforts. Prior to Ilypsa, he joined Symyx in 1998 as a Staff Scientist, and was later promoted to Director of Business Development. Gerrit received his Ph.D. in polymer chemistry from the Max-Planck-Institute for Polymer Research in Mainz, Germany. He conducted postdoctoral research at Stanford University and the IBM Almaden Research Center.